Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of Pomalidomide in Combination With Liposomal Doxorubicin in Patients With Advanced or Refractory Kaposi Sarcoma

NCT02659930 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02659930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02659930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of Pomalidomide in Combination With Liposomal Doxorubicin in Patients With Advanced or Refractory Kaposi Sarcoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 13, 2016
Completion date
January 1, 2029
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kaposi sarcoma